Brief: Biofrontera Achieves Key Milestone In Phase 3 Study Of Ameluz-PDT In Treatment Of sBCC
08/01/2025 16:25
Jan 8 (Reuters) - Biofrontera Inc BFRI.O :
* BIOFRONTERA INC. ANNOUNCES ACHIEVEMENT OF KEY MILESTONE IN
PHASE
3 STUDY OF AMELUZ®-PHOTODYNAMIC THERAPY (PDT) IN THE TREATMENT
OF SUPERFICIAL BASAL CELL CARCINOMA (SBCC)
* BIOFRONTERA INC - FOLLOW-UP DATA TO BE INCLUDED IN FDA
SUBMISSION EXPECTED Q3 2025
Source text: ID:nGNX3C1kk7
Further company coverage: BFRI.O
(((( Reuters.Briefs@thomsonreuters.com ;));))
Recent news on Biofrontera
See all newsBrief: Biofrontera Submits Supplemental New Drug Application To FDA To Expand Ameluz® Red Light Pdt To Actinic Keratoses On The Full Body
Biofrontera Inc reports results for the quarter ended June 30 - Earnings Summary
Biofrontera Q2 revenue rises on higher volume, pricing
Biofrontera Inc expected to post a loss of 10 cents a share - Earnings Preview
Biofrontera Q1 revenue rises on higher Ameluz sales